AREG is a predictive biomarker in the treatment of colorectal cancer [33] and promotes the progression of cancers via the AREG/EGFR pathway in pancreatic cancer, breast cancer and ovarian cancer [34–36], suggesting that AREG may be an attractive target in HNSCC. This evidence concerns the gene EGFR and ovarian cancer.